Advanced search
Publication Cover
Journal of Nutritional & Environmental Medicine Volume 8, 1998 - Issue 2
Journal homepage
7
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Thrombosis and Heart Attacks with Contraceptive and Menopausal Hormones

ELLEN C. G. GRANT 20 Coombe Ridings, Kingston-upon-Thames, Surrey KT2 7JU, UK
Pages 159-167 | Published online: 13 Jul 2009

  • Jordan WM. Pulmonary embolism. Lancet 1961; 2: 1146-7.
  • Grant ECG. Relation between headaches from oral contraceptives and development of endometrial arterioles. Br Med J 1968; iii: 402-5.
  • Chasan-Taber L, Stampher MJ. Oral contraceptives and risk of arterial disease: epidemiological evidence on acute and long-term effects. In: Hannaford PC, Webb AMC, eds. Evidence-guided Prescribing of the Pill. New York: Parthenon, 1996; 49-60.
  • Grant ECG. Venous effects of oral contraceptives. BMJ 1969; iv: 73-7.
  • Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al. Evidence that currently available pills are associated with vascular disease: venous disease. In: Hannaford PC, Webb AMC, eds. Evidence-guided Prescribing of the Pill. New York; Parthenon, 1996; 61-76.
  • Grant ECG. Sexual Chemistry. London: Reed Books, 1994.
  • Grant ECG. Hormone balance of oral contraceptives. J Obstet Gynaecol Br Commonwealth 1967; 74: 908-18.
  • Grady D, Gebretsadik T, Ernster V, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304-13.
  • Grant ECG. Why women should not be given hormone replacement therapy. Br J Hosp Med 1989; 41: 590 and 42: 159.
  • Beresford SAA, Weiss NS, Voigt, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349: 458-61.
  • Inman WHW, Vessey MP, Westerholm B, et al. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. BMJ 1970; 2: 203-9.
  • Daniel DG, Campbell H, Turnbull A. Puerperal thrombosis and suppression of lactation. Lancet 1967; 2: 287.
  • Sullivan JM, van der Zwagg R, Hughes JP, et al, Estrogen replacement and coronary artery disease; effect on survival of postmenopausal women. Arch Intern Med 1990; 150: 2557-62.
  • Hunt K, Vessey M, McPherson K, et al. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987; 94: 620-35.
  • Grant ECG. Changing oral contraceptives. Editorial. BMJ 1969; 4: 789-91.
  • Grant ECG. Long-term dangers of hormonal treatment. Lancet 1994; 43: 926.
  • Grady D, Rubin S, Pettiti D, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37.
  • Vandenbrouke JP. Postmenopausal oestrogen and cardioprotection. Lancet 1991; 337: 833-4.
  • Barret-Connor E. Postmenopausal oestrogen and prevention bias. Ann Intern Med 1991; 115: 455-6.
  • Hemminki E, Sihvo S. A review of postmenopausal hormone therapy recommendations: potential for selection bias. Obstet Gynecol 1993; 82: 1021-8.
  • Posthuma WF, Westendorf RG, Vandenbrouke JP. Cardioprotective effect of hormone replacement therapy is the evidence biased'? BMJ 1994; 308: 1268-9 and 309: 809.
  • Grant ECG, Antony HM, Myhill S, et al, Breast cancer and hormone exposure. Lancet 1996; 348: 682.
  • Hunt, K, Vessey M. Long-term effects of postmenopausal hormone therapy. Br J Hosp Med 1987, 38: 450-3 and 456-60.
  • Van der Graaf V, De Kleijn NJJ, van der Schoune YT. Menopause and cardiovascular disease. J Psychom Obstet Gynecol 1997; 18: 113-20.
  • Petitti DB, Wingerd J, Pellagrin P, et al. Oral contraceptives, smoking, and other factors in relation to risk of venous thromboembolic disease. Am J Epidemiol 1978; 108: 480-5.
  • Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
  • World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995). Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 582-8.
  • Jick H, Jick SS, Gurewich V, et al, Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with different progestagen components. Lancet 1995; 346: 1589-93.
  • Bloemenkamp KWM, Rosendaal FR, Helerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen. Lancet 1995; 346: 1593-6.
  • Spitzer WO, Lewis MA, Heinemann LAJ, et al. On behalf of the Transnational Research Group on Oral Contraceptives and the Health of Young Women. Third generation of oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996; 312: 83-8.
  • Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users, of hormone replacement therapy. Lancet 1996; 348: 977-80.
  • Jick H, Derby LE, Myers MW, et al. Risk of hospital admission for idiopathic thromboembolism among users of postmenopausal oestrogens. Lancet 1966; 348: 981-3.
  • Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1966; 348: 983-7.
  • Rosing J, Tans G, Nicolaes GAF, Thomassen R, et al. Oral contraceptive and venous thrombosis: different sensitivities to activated protein C in women using second and third generation oral contraceptives. Br J Haemat 1997; 97: 233-8.
  • Lowe GDO, Rumby A, Woodward M, et al. Oral contraceptives and venous thrombosis. Lancet 1997; 349:1623.
  • Meinardi JR, Henekens CMA, Hering MP, et al. Acquired APC resistance related to oral contraceptives and pregnancy and its possible implications for clinical practice. Blood Coag Fibrinol 1997; 8: 152-4.
  • Ullery JC. Thromboembolic complications of pregnancy and the puerperium. Am J Obstet Gynecol 1954; 68: 1943-60.
  • Burkitt RL. Increase in idiopathic thromboembolism. ID: Goldzeiher JW, Rice-Wray E, eds. Oral contraception-mechanism and management. Springfield, Illinois: CC Thomas, 1966; 101.
  • Goldzeiher JW, Rice-Wray E. Oral contraception--mechanism and management. Springfield, Illinois: CC Thomas, 1966; 101-4.
  • Hughes G. The Hughes Syndrome. BMJ 1983; 287: 1088-9.
  • WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international case control study. Lancet 1997; 349: 1202-9.
  • Engel HJ, Engel E, Lichtlen P. Coronary atherosclerosis and myocardial infarction in young women--role of oral contraceptives. Fur Heart 1983; 4; 1-8.
  • Engel HJ, Hundeshagen H, Lichtlen P. Tsansmural infarction in young women taking oral contraceptives. Evidence of reduced regional coronary flow in spite of normal coronary arteries. Br Heart J 1983; 39: 477-84.
  • Jugdutt BI, Stevens GF, Zachs DJ, Lee SJK, Taylor RV Myocardial infarction, oral contraceptives, cigarette smoking, and coronary arterty spasm in young women. Am Heart J 1983; 106: 757-61.
  • Klench H. Direct and indirect effects of nicotine on the arterial vascular system. Zeitschrift fur kardiologie 1974; 63: 494-510.
  • Hemminki E. Oral contraceptives and breast cancer. BMJ 1996; 313: 63-4.
  • Rosendaal FR, Siscovick SM, Beverly RK, et al. Factor V Lieden (resistance to activated protein C) increased risk of myocardial infarction in young women. Blood 1997; 89: 2817-21.
  • Crook D. Role of screening for vascular disease in pill users: lipids and lipoproteins. In: Hannaford PC, Webb AMC, eds. Evidence-guided Prescribing of the Pill. New York: Parthenon, 1996; 89-98.
  • Committee on Safety of Medicines. Combined oral contraceptives and venous thromboembolism. London: Committee on Safety of Medicines, 1995.
  • Grant ECG. Third-generation oral contraceptives and venous thrombosis. Lancet 1997; 349: 733.
  • Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997; 7101: 149-53.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.